The Precision Spectra system, which has four lead ports offering more coverage of the spinal cord, is designed to provide improved pain relief in chronic pain patients.

In addition, the lead ports provide physicians with more flexibility to treat patients’ pain at time of implant and adapt to changing pain patterns in the future.

The SCS system also includes an implantable pulse generator which delivers electrical pulses to leads with stimulating contacts and mask pain signals traveling to the brain.

To study the efficacy of the system, the first implant was performed at the Basildon and Thurrock University Hospitals in the UK, according to the company.

Basildon and Thurrock University Hospitals pain medicine and neuromodulation consultant Dr Simon Thomson said previously, the SCS system was available with four to eight contacts.

"Now, by doubling the number of contacts to 32 while providing a dedicated power source for each contact, the Precision Spectra System advances our ability to provide pain relief," Thomson added.

In addition, the company has begun a prospective, multi-center, single arm study, named OPTIONS trial, to further characterize the benefits of 32 contact option in Precision Spectra.

The company has also commenced a cross-sectional, multicenter MAP trial to identify the prevalence of multiple areas of pain in SCS-eligible patients with certain diseases.